

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 to 2 (Cancelled)

Claim 3 (Previously Presented) A compound of claim 18 wherein:

R^2 is (C_1-C_6) alkyl substituted with $-NR^4R^5$ or $-C(=O)NR^4R^5$;

R^4 is (C_1-C_6) alkyl substituted with $-S(=O)CH_3$, $-NHC(=O)CH_3$ or $-C(=O)NR^7R^8$;

R^5 is H or methyl; and

R^7 and R^8 are the same or different and are H or methyl.

Claim 4 (Cancelled)

Claim 5 (Presently Amended) A compound of claim 18 wherein:

R^2 is (C_1-C_6) alkyl substituted with $-S(=O)R^3$;

R^3 is (C_1-C_6) alkyl optionally substituted with one to three groups selected from $-S(=O)R^6$, $-SO_2R^6$, $-NR^7R^8$, $-OR^7$, $-NRC(=O)R^7$, $-NR^7SO_2R^7$, $-NR^7SO_2R^6$,

$-C(=O)NR^7R^8$; and $-O-C(=O)NR^7R^8$; and wherein

R^6 is (C_1-C_6) alkyl and R^7 , R^8 and R^9 are the same or different and are H or (C_1-C_6) alkyl.

Claim 6 (Previously Presented) A compound of claim 18 wherein R^2 is (C_1-C_6) alkyl substituted with $-S(=O)R^3$; and R^3 is (C_1-C_6) alkyl.

Claim 7 (Cancelled)

Claim 8 (Previously Presented) A compound of claim 18 wherein:

R^2 is $Q^1-Q^2-Q^3-Q^4$;

Q^1 is a single bond;

Q^2 is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom;

Q^3 is $-CH_2-$;

Q^4 is a 5-membered aromatic heterocycle comprising 2 nitrogen atoms, said heterocycle being optionally substituted with methyl;

the atom of Q^2 bound to Q^1 is a carbon atom; and

the atom of Q^4 bound to Q^3 is a carbon atom.

Claim 9 (Previously Presented) A compound of claim 18 wherein R^1 is $-Cl$ or $-F$.

Claim 10 (Previously Presented) A compound of claim 18 wherein m is 2.

Claim 11 (Previously Presented) A compound according to claim 18 and selected from the group consisting of:

5'-(2-[(2-amino-2-oxoethyl)amino]ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-chloro-5'-(methylsulfinyl)methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

5'-(2-[(2-(acetylamino)ethyl)amino]ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-(3-(methylsulfinyl)propoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-(methylsulfinyl)methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;
and

8'-fluoro-5'-(2-[(1-(1H-pyrazol-3-ylmethyl)azetidin-3-yl)oxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one.


Claim 12 (Cancelled)

Claim 13 (Previously Presented) A method of treating acquired immune deficiency syndrome (AIDS) in a mammal, comprising administering to said mammal in need thereof a compound of claim 18.

Claims 14 to 16 (Cancelled)

Claim 17 (Previously Presented) A pharmaceutical composition comprising a compound of claim 18 together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.

Claim 18 (Previously Presented) A compound of formula (I):



wherein

m is 1, 2 or 3;

R¹ is selected from CH₃, Cl, Br and F;

R² is selected from

(a) Q¹-Q²-Q³-Q⁴ wherein:

Q¹ is a single bond or a linear or branched (C₁-C₄)alkylene group;

Q² is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom;

Q³ is a linear (C₁-C₄)alkylene group;

Q⁴ is a 5 or 6-membered, aromatic heterocycle comprising 1 to 4 nitrogen atoms, said heterocycle being optionally substituted with methyl;

the atom of Q² bound to Q¹ is a carbon atom; and

the atom of Q⁴ bound to Q³ is a carbon atom;

(b) (C₁-C₆)alkyl, said alkyl group being substituted with a group selected from OR⁴, COOR⁴, NR⁴R⁵, NRC(=O)R⁴, C(=O)NR⁴R⁵ and SO₂NR⁴R⁵, wherein:

R is H or (C₁-C₆)alkyl;

R⁴ is (C₁-C₆)alkyl substituted with 1 to 3 groups selected from S(=O)R⁶, SO₂R⁶, NRC(=O)R⁷, NR⁷SO₂R⁶, C(=O)NR⁷R⁸, O-C(=O)NR⁷R⁸ and SO₂NR⁷R⁸, wherein R⁶ is (C₁-C₆)alkyl and R⁷, R⁷ and R⁸ are the same or different and are selected from H and (C₁-C₆) alkyl; and

R⁵ is selected from R⁴, H and (C₁-C₆)alkyl;

(c) (C₁-C₆)alkyl, said alkyl group being:

substituted with 1 to 3 groups selected from $OC(=O)R^{4a}$, SR^{4a} , $S(=O)R^3$, NR^aCOOR^{4a} , $NR^a-C(=O)-NR^{4a}R^{5a}$, $NR^a-SO_2-NR^{4a}R^{5a}$, and $NR^a-SO_2-R^3$, and

optionally substituted with OH or OCH_3 ;

wherein

R^a is selected from H and CH_3 ;

R^3 is $(C_1-C_6)alkyl$, unsubstituted or substituted with 1 to 3 groups, selected from F, CN, $S(=O)R^6$, SO_3H , SO_2R^6 , $C(=O)-NH-SO_2-CH_3$, OR^7 , SR^7 , $COOR^7$, $C(=O)R^7$, $O-C(=O)NR^7R^8$, NR^7R^8 , $NR^aC(=O)R^7$, $NR^aSO_2R^6$, $C(=O)NR^7R^8$ and $SO_2NR^7R^8$, wherein R^6 is $(C_1-C_6)alkyl$ and R^a , R^7 and R^8 are the same or different and are selected from H and $(C_1-C_6)alkyl$;

R^{4a} and R^{5a} are the same or different and are selected from H and R^3 ;

their racemic forms, their isomers or their pharmaceutically acceptable salts.